National Science Foundation

Eascra Biotech specializes in developing DNA-inspired, Janus base nanomaterials for targeted drug delivery. Their platform, based on three generations of DNA nanotubes, is designed to effectively penetrate and treat hard-to-reach tissues like articular cartilage, the central nervous system, and solid tumors. These nanomaterials can encapsulate and stabilize various therapeutic agents, including mRNA, siRNA, proteins, and gene-editing tools, at room temperature, enhancing their efficacy and reducing systemic exposure.

Auxilium Health is creating low-cost, smart biomaterials for difficult-to-heal wounds.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

Amphix Bio is engaged in the development of advanced therapeutic materials aimed at regenerative medicine. The company specializes in creating nanofiber materials that replicate the structure and dynamic characteristics of human tissues. By integrating biological signals, these materials instruct cells to activate regenerative processes. Amphix Bio's innovations enable the development of therapies designed to repair a variety of tissues, including bone, cartilage, muscle, cardiovascular tissues, and the brain and spinal cord. The promising results observed in both preclinical and clinical trials highlight the potential of Amphix Bio's approach in transforming therapeutic applications in medicine.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

LiteraSeed operates a clinically validated digital health platform designed to enhance communication between healthcare providers and low health literate patient populations. The platform addresses significant challenges faced by public health providers, particularly in serving patients who may not speak English or have other communication barriers. By enabling these individuals to accurately and remotely self-report symptoms, LiteraSeed aims to prevent costly misdiagnoses, adverse events, and unnecessary emergency room admissions. This approach not only improves access to care for disadvantaged patients but also makes clinical encounters more productive, fostering better understanding of health status and overall patient outcomes.

The University of Washington is a prominent educational institution located in Seattle, Washington, founded in 1861. It offers a diverse range of undergraduate, graduate, and research programs across various fields, including business, social sciences, science, law, medicine, and public affairs. The university comprises several specialized schools, such as the College of Engineering, School of Dentistry, School of Pharmacy, School of Public Health and Community Medicine, School of Business, School of Humanities and Sciences, School of Law, School of Nursing, and College of Ocean and Fishery Sciences. In addition to its academic offerings, the university is dedicated to fostering innovation through CoMotion, which provides resources and support to help researchers and students translate their ideas into tangible societal and economic benefits.

Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.

The Wistar Institute is the first independent institution in the United States dedicated to medical research and training, recognized for its significant contributions to biomedical science. Originally established as an anatomical teaching museum, it has transformed into a leading center for basic biomedical research and was designated a National Cancer Institute Cancer Center in 1972. The institute specializes in research areas including immunology, infectious diseases, and vaccine development. Its groundbreaking discoveries have facilitated the creation of vaccines for diseases such as rabies, rubella, and rotavirus, as well as the identification of genes linked to various cancers, including breast, lung, and prostate cancer. Additionally, Wistar has played a crucial role in advancing monoclonal antibodies and other vital research technologies, fostering a collaborative environment aimed at addressing critical health challenges.

The University of Louisville is a public research university that offers a wide range of undergraduate and graduate programs across various disciplines. It is particularly known for its contributions to health, engineering, and the humanities. The university actively engages with community partners to enhance its academic and research initiatives, thereby creating a significant impact on education, healthcare, and research industries. Additionally, the University of Louisville School of Dentistry serves as a specialized institute within the university, focusing on dental education and training.

The University of Michigan, one of the largest universities in the Midwest, offers a diverse array of academic programs that attract over 40,000 undergraduate, graduate, and professional students. Its renowned schools include the Stephen Ross School of Business, the College of Engineering, and prominent law and medical schools. The university also has a vibrant arts scene, highlighted by its Musical Theatre program and the annual Ann Arbor Film Festival, which draws filmmakers globally. In addition to its educational endeavors, the University of Michigan actively manages a significant endowment, investing in alternative assets such as private equity, real estate, and infrastructure to support its mission and enhance its resources. The institution consistently ranks highly in national assessments, reflecting its commitment to academic excellence and innovation.

MelliCell is focused on combating chronic diseases through innovative tissue engineering technology, specifically targeting fat cells as a source of therapeutic adipokines. Their platform enables the conversion of human stem cells into large, mature fat cells, which can be used to develop drug therapies aimed at reducing fat mass while preserving lean mass. This unique approach is designed to address conditions such as obesity, diabetes, aging, oncology, and inflammation. MelliCell's team has garnered recognition through awards and partnerships with leading biopharma companies, validating their technology. By advancing oral small molecules that shrink fat cells, MelliCell aims to enhance health outcomes and improve the quality of life for individuals affected by these diseases.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

Astria Biosciences, based in Pittsburgh, specializes in developing innovative diagnostic and therapeutic solutions for cerebrovascular diseases. The company focuses on addressing neurosurgical challenges through molecular biology, advanced analytics, and small-molecule inhibitors, aiming to provide non-surgical alternatives for neurovascular conditions where surgery is currently the primary option.

Serious research-based academics in Technology and the Engineering, Biological and Computer Sciences on a remodeled, state-of-the-art campus is what you will find at New Jersey Institute of Technology (NJIT) in Newark, New Jersey. Applied Physics, Biocomplexity, Biomedical Engineering, Civil Engineering, Mathematical Engineering and Medical Informatics Technology are some of the more than 70 undergraduate degrees offered at NJIT. There are also more than 15 graduate programs. Not only do nearly 100% of faculty hold doctorates, but they also work on pioneering research with students and with local businesses and organizations as well. Research areas include such fields as Biological Sciences, Biomedical Studies, Nanotechnologies and Wireless Communications. Opportunities for work abound for NJIT grads in great part because of the quality of student training and the reputation of the school. Also important are the internships, which the school arranges for students while they’re still studying. Classrooms and research centers aren’t the only place on the NJIT campus that employ the most current technologies. The renovated campus recreation areas, computer labs, and restaurants add to the contemporary look and feel of the NJIT experience. Since Newark is the largest city in New Jersey there are also many employment opportunities available in the area. With its restaurants and cultural activities, Newark also provides much in the way of recreation and culture. New York City is also only 20 minutes away, so there is even more to be found in the off-campus experience. Admission to NJIT is competitive and undergraduates who are accepted usually have high grades and test scores. Many eligible undergraduates receive some form of financial aid.

Lapovations is a healthcare company founded in 2016 and headquartered in Fayetteville, Arkansas. It focuses on the development and manufacturing of innovative medical devices specifically designed for laparoscopic surgery. The company's mission is to redefine laparoscopy by creating devices that minimize invasiveness, simplify surgical procedures, and enhance patient outcomes. Through its cutting-edge technology, Lapovations aims to enable medical professionals to perform surgeries with greater safety and efficiency.

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for various debilitating conditions. The company employs a modular approach to research and development, utilizing established technologies in innovative ways to address well-understood disease mechanisms. By focusing on clinically validated molecules and targeted treatment strategies, Remedium Bio aims to create effective therapies for conditions within rheumatology, endocrinology, and neurology. Its pipeline includes promising gene therapy candidates designed to tackle a wide range of diseases, including immune and age-related disorders.

Quantivly, Inc. is a technology company based in Somerville, Massachusetts, that specializes in artificial intelligence solutions for radiology. Founded in 2019, it focuses on developing software that manages and analyzes MRI imaging workflows. The company's platform enables radiology providers to access a vendor-neutral, granular source of operational data by analyzing and harmonizing scanner information. This capability supports radiology departments and imaging centers in making data-driven decisions, improving operational efficiency, and enhancing patient-centered healthcare. By offering tools for data liquidity and analysis, Quantivly aims to increase access to medical imaging and drive advancements in research and patient care within the radiology sector.

The University of Washington is a prominent educational institution located in Seattle, Washington, founded in 1861. It offers a diverse range of undergraduate, graduate, and research programs across various fields, including business, social sciences, science, law, medicine, and public affairs. The university comprises several specialized schools, such as the College of Engineering, School of Dentistry, School of Pharmacy, School of Public Health and Community Medicine, School of Business, School of Humanities and Sciences, School of Law, School of Nursing, and College of Ocean and Fishery Sciences. In addition to its academic offerings, the university is dedicated to fostering innovation through CoMotion, which provides resources and support to help researchers and students translate their ideas into tangible societal and economic benefits.

The University of Michigan, one of the largest universities in the Midwest, offers a diverse array of academic programs that attract over 40,000 undergraduate, graduate, and professional students. Its renowned schools include the Stephen Ross School of Business, the College of Engineering, and prominent law and medical schools. The university also has a vibrant arts scene, highlighted by its Musical Theatre program and the annual Ann Arbor Film Festival, which draws filmmakers globally. In addition to its educational endeavors, the University of Michigan actively manages a significant endowment, investing in alternative assets such as private equity, real estate, and infrastructure to support its mission and enhance its resources. The institution consistently ranks highly in national assessments, reflecting its commitment to academic excellence and innovation.

Case Western Reserve University (CWRU) is a private research university located in Cleveland's University Circle. Established in 1843, it comprises various schools including Medicine, Law, Engineering, Arts and Sciences, Nursing, Social Sciences, Dental Medicine, Management, and Mandel School of Applied Social Sciences. CWRU is renowned for its biomedical discoveries, medical education, and top-ranked programs such as international law, health law, and intellectual property law. It offers practical experiences like real-client work and full-time practice experiences to students across various disciplines. The university is accredited by several professional associations and holds membership in the Association of American Universities.

University of Minnesota provides baccalaureate, master’s, and doctoral degrees in medicine, business, law, liberal arts, science, engineering, and architecture fields. They also provide education services to communities through science-based knowledge and training.

GENASSIST is a genetics company that provides assisted reproductive technology genetic consultation and testing services.

Malcova is an early-stage medical device startup focused on developing advanced imaging solutions for the detection and diagnosis of breast cancer, particularly in women with dense breast tissue. The company employs its proprietary Narrow-Beam Computed Tomography technology, which enhances the effectiveness of medical imaging compared to traditional methods like mammography and tomosynthesis. Additionally, Malcova integrates artificial intelligence in its software to improve the functionality of its devices. The aim is to provide clinicians with tools that facilitate accurate diagnosis while ensuring that the imaging process is safe, comfortable, and accessible for patients. Through these innovations, Malcova seeks to enhance the overall experience and outcomes for breast cancer detection and treatment.

The University of Louisville is a public research university that offers a wide range of undergraduate and graduate programs across various disciplines. It is particularly known for its contributions to health, engineering, and the humanities. The university actively engages with community partners to enhance its academic and research initiatives, thereby creating a significant impact on education, healthcare, and research industries. Additionally, the University of Louisville School of Dentistry serves as a specialized institute within the university, focusing on dental education and training.

Lilu Inc. is a women’s health company based in New York, specializing in innovative solutions for new mothers. Founded in 2016, the company develops tech-enabled devices aimed at improving the breastfeeding experience. Its flagship product, the Lilu massage bra, is an FDA Class device that employs patented pneumatic massage technology to mimic natural breastfeeding motions, thereby increasing milk output and reducing discomfort associated with traditional breast pumps. Lilu's products, including the massage bra and pumping cover, are sold online and have received positive feedback from customers, who appreciate their effectiveness and user-friendly design. By addressing common challenges faced by breastfeeding mothers, Lilu seeks to empower women while promoting a more manageable breastfeeding journey.

Metfora is focused on developing a blood test designed to identify chronic lung and heart disorders, as well as cancers, in their early stages. The company employs artificial intelligence to analyze patterns in circulating metabolites within a patient's blood, enabling the detection of diseases that may not present significant symptoms initially. This innovative approach aims to assist both doctors and patients by providing timely insights for diagnosing serious health conditions, ultimately enhancing early intervention and treatment options.

ReSuture is a company that specializes in creating high-fidelity physical simulations for surgical training, particularly focusing on open vascular procedures. Established in 2019, its primary goal is to enhance patient outcomes and minimize surgical complications by providing a superior training experience for aspiring surgeons. The company develops advanced surgical instruments that address challenges in medical simulation, allowing users to practice vascular surgical skills in a controlled environment. These instruments replicate the mechanical properties of human vascular tissue, enabling realistic simulations that improve psychomotor skills and reduce training time for medical practitioners.

BLOCKsyncop is focused on creating a non-invasive, real-time clinical monitoring device aimed at anesthesiologists. The technology is designed to offer objective measurements that quantify the controlled delivery and effectiveness of neural blocks for pain management. By providing healthcare professionals with this tool, BLOCKsyncop seeks to reduce the incidence of failed neural blocks, minimize anesthetic toxicity, and optimize the overall analgesic needs of patients.

PneumoNIX Medical is focused on creating gel-based technologies aimed at preventing complications related to percutaneous procedures, particularly in the context of soft tissue biopsies. The company's innovative medical devices are designed to minimize the risk of collapsed lung complications that may occur during CT-guided lung biopsies. By addressing these critical issues, PneumoNIX Medical seeks to enhance patient safety and improve outcomes in medical interventions that involve needle insertions.

VIVIFI Medical is a Houston-based company focused on developing innovative laparoscopic technology aimed at enhancing patient outcomes in men’s health. The company's flagship product is a suture-less device that facilitates the rapid connection of two blood vessels, specifically targeting conditions such as varicocele and benign prostatic hyperplasia (BPH). By improving surgical techniques for these medical issues, VIVIFI Medical seeks to provide effective solutions that surpass current treatment standards, thereby improving the quality of life for patients dealing with male infertility and related health challenges.

The University of Louisville is a public research university that offers a wide range of undergraduate and graduate programs across various disciplines. It is particularly known for its contributions to health, engineering, and the humanities. The university actively engages with community partners to enhance its academic and research initiatives, thereby creating a significant impact on education, healthcare, and research industries. Additionally, the University of Louisville School of Dentistry serves as a specialized institute within the university, focusing on dental education and training.

Atom Bioworks focuses on developing a pattern-recognition enabled platform that combines DNA, antibody mimics, and advanced computational techniques for the detection and treatment of infectious diseases and cancer. The platform utilizes computational biology, quantum chemistry, software, and machine learning to identify specific surface protein patterns associated with diseases. By creating corresponding pattern-matching constructs, Atom Bioworks aims to enhance researchers' capabilities in early diagnosis and therapeutic interventions, ultimately improving medical applications in the fight against infectious diseases and cancer.

The University of Michigan, one of the largest universities in the Midwest, offers a diverse array of academic programs that attract over 40,000 undergraduate, graduate, and professional students. Its renowned schools include the Stephen Ross School of Business, the College of Engineering, and prominent law and medical schools. The university also has a vibrant arts scene, highlighted by its Musical Theatre program and the annual Ann Arbor Film Festival, which draws filmmakers globally. In addition to its educational endeavors, the University of Michigan actively manages a significant endowment, investing in alternative assets such as private equity, real estate, and infrastructure to support its mission and enhance its resources. The institution consistently ranks highly in national assessments, reflecting its commitment to academic excellence and innovation.

CPR Therapeutics is a medical device company focused on developing an advanced automated system for cardiopulmonary resuscitation (CPR). This next-generation technology integrates multiple innovations into a single, easy-to-use system designed for emergency situations. The automated CPR system enhances blood flow and the effectiveness of electrical countershocks, achieving results that were previously only possible in laboratory environments. By combining chest compressions with artificial ventilation, the system aims to preserve brain function and restore spontaneous blood circulation and breathing in individuals experiencing cardiac arrest. This technology represents a significant advancement in emergency medical care, with the potential to improve survival rates in critical situations.

BioSuperior Technology is a preclinical biotherapeutics company specializing in lung disease treatments. It has developed a novel, synthetic pulmonary surfactant prototype called BioSurf, which directly treats lung conditions and delivers potent drugs to restore normal lung function. This technology has the potential to repair damaged lung tissue and may also treat other microvasculature-related illnesses like hemorrhagic stroke and chronic kidney disease.

Bespoke Biotherapeutics provides an effective natural immune response and overcomes the limitations of currently approved immunotherapies against cancer by inventing novel, customised living drugs called engineered B-cell therapeutics. They offer customised B-cell sourcing, isolation, activation, culture expansion, and non-viral genetic engineering methodologies uniquely suited to optimise commercial B-cell products for infusion.

AngioInsight is a fully automated computer-based platform to assist with coronary angiogram video interpretation.

Scopi Medical is a healthcare technology company specializing in next-generation medical optical imaging. It provides a hardware platform and advanced AI/ML software to enable accurate, early detection and interpretation of conditions, directly at primary care clinics. The company's innovative technology allows practitioners, with the aid of remote specialists, to visualize and treat areas of concern, such as chronic nasal conditions like rhinosinusitis, safely and efficiently.

CardioPhi, a Harvard Innovation Labs company, specializes in developing artificial intelligence solutions for the automatic and reliable interpretation of electrocardiograms (ECGs). Their primary goal is to enhance outcomes for individuals with cardiac arrhythmias and decrease public expenditure on cardiovascular diseases, thereby aiding clinicians in assessing heart functionality more effectively.

Tiny Cargo specializes in a unique drug delivery system utilizing non-immunogenic bovine milk-derived exosomes. This innovative approach allows for the effective oral or intravenous administration of potent therapeutics. The company focuses on delivering treatments for various serious health conditions, including ischemic heart disease, gastrointestinal radiation disease, and glioblastoma multiforme, among others. By leveraging its technology, Tiny Cargo aims to enhance the delivery of peptide drugs, making it applicable to a wide range of current peptide therapeutics and improving patient outcomes in the treatment of neurological and other pathologies.

Claria Medical is a pre-commercial medical device start-up focused on developing innovative solutions for women's healthcare, specifically targeting unmet needs in gynecologic surgery. The company specializes in creating minimally invasive surgical tools designed to enhance procedures such as hysterectomy and myomectomy. Claria Medical has received recognition for its early achievements, including a “Safer Technologies Designation” from the U.S. Food and Drug Administration. Additionally, the company has secured funding through private investments as well as grants from the National Science Foundation and the National Institutes of Health to support its product development efforts. By providing specialized surgical assistance, Claria Medical aims to improve outcomes for women undergoing these procedures.

BrilliantMD specializes in claims management services tailored for the healthcare sector, focusing on enhancing transparency in healthcare data and the claims process. The company has developed a software solution that addresses issues related to claims denials by leveraging advanced technologies such as artificial intelligence, machine learning, and blockchain. This innovative approach aims to provide users with valuable insights and data-driven decision-making capabilities, ultimately helping healthcare organizations improve revenue and streamline their operations.

Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.

JelikaLite specializes in developing medical equipment for children with autism spectrum disorders, focusing on non-invasive methods to enhance brain health. Their primary product is a wearable device that integrates infrared light, EEG sensors, and an artificial intelligence personalization platform. This therapeutic device aims to reduce the symptoms of autism by promoting improvements in speech, decreasing anxiety, and enhancing responsiveness in pediatric patients. By utilizing innovative therapies, JelikaLite seeks to provide lasting benefits for children dealing with autism, emphasizing a commitment to advancing pediatric neurological health.

Relavo, LLC, founded in 2018 and based in Baltimore, Maryland, is a medical device company focused on improving the treatment of kidney failure patients through innovative technology. The company's flagship product, PeritoneX, is designed to enhance home dialysis by reducing the risk of infection associated with peritoneal dialysis. This in-line connection device works by disinfecting all connection points in the dialysis system before treatment, thereby aiming to minimize the occurrence of peritonitis. Relavo's approach seeks to make home dialysis safer and more accessible for patients, ultimately improving their quality of life.

Qualia Oto is a biomedical device company established in 2017 in Dallas, Texas, specializing in advanced cochlear implant technology aimed at improving the lives of individuals with hearing impairments. The company focuses on developing innovative devices that incorporate shape-changing polymers and matrix-addressed electrode arrays, which facilitate higher channel counts in cochlear implants and auditory brainstem implants. This technology allows for more precise stimulation of the auditory nerve, potentially leading to enhanced hearing capabilities. Qualia Oto's commitment to integrating machine learning into its stimulation techniques further aims to refine auditory experiences for users, addressing both medical and personal hearing needs.

Oxalo Therapeutics is focused on developing innovative drug therapies aimed at treating rare kidney diseases and preventing recurring kidney stones. The company specifically targets primary hyperoxaluria and other oxalate-related pathologies through a novel approach that utilizes a gut bacterium to facilitate the safe removal of oxalate from the body. By mimicking natural mechanisms, Oxalo Therapeutics seeks to provide effective treatment options for patients suffering from conditions associated with high levels of oxalate, thereby improving their quality of life and reducing the incidence of kidney stone recurrence. The company's expertise in the microbiome and translational research underpins its commitment to advancing early-stage technology in the field of kidney health.

Uniphage is a biotechnology company that specializes in developing innovative solutions to combat bacterial infections, with a focus on agriculture. It combines the power of bacteriophages, naturally occurring viruses that infect bacteria, with artificial intelligence to create precise and safe antimicrobial products. Uniphage's primary goal is to reduce the use of harmful fungicides, bactericides, and antibiotics in plant agriculture by providing more efficient and eco-friendly alternatives. By using AI algorithms to predict the effectiveness of bacteriophages against specific bacterial infections, Uniphage aims to accelerate the development of new pesticides, thereby minimizing risks to human health and the environment.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.

Simmbion specializes in innovative therapeutic solutions by utilizing symbionts to manufacture therapeutic agents directly within the human body, effectively transforming it into a living pharmacy. This technology aims to eliminate the challenges associated with traditional therapy manufacturing, such as the need for complex production processes, repeated injections, and temperature-sensitive storage. By providing a single injection that lasts up to 12 weeks, Simmbion's approach addresses supply chain disruptions and enhances affordability and accessibility of cell therapies for diverse patient populations. Their adaptable and universally immune compatible systems focus on delivering biological drugs directly in vivo, supporting a patient-centric and outcome-driven healthcare model while minimizing the risks of infections and immune rejection.

AccuBreath is a medical device company focused on creating an affordable and ultraportable ventilator designed for respiratory support. The company has developed a non-invasive ventilation and respiration monitoring system that offers gentle assistance to patients, particularly during sedation for medical procedures. This innovative ventilator helps to reduce airway obstruction, allowing healthcare professionals to maintain effective ventilation while minimizing potential complications, such as stomach inflation. AccuBreath aims to enhance patient care through its advanced respiratory technology, making high-quality respiratory support more accessible in various medical settings.

Cryptyx Bioscience is a biopharmaceutical company focused on discovering new therapeutic natural products from bacteria without the use of genetics or cloning. Their innovative platform aims to activate silent biosynthetic gene clusters within bacteria, allowing them to unlock the full potential of culturable microbes. By employing a bioactivity-first approach, Cryptyx seeks to rapidly identify new antibiotics and antiviral drugs, addressing critical needs in combating infectious diseases prioritized by health organizations. The company's technology is designed to provide a broad range of medical services and therapeutic applications, ultimately enhancing treatment options for patients.

Iaso Therapeutics, founded in 2018 and based in East Lansing, Michigan, is a biotechnology company focused on developing vaccines aimed at improving human health and treating infectious diseases. The company’s platform is dedicated to creating vaccines for serious illnesses, including smallpox, yellow fever, and tetanus. By providing healthcare professionals with innovative technologies, Iaso Therapeutics seeks to enhance public health outcomes and address critical health challenges.

Ai-Ris offers automated retinal examinations for primary care. Their retinal imaging system allows general practitioners to screen for diabetic retinopathy without the presence of a specialist. This system consists of a portable headset that uses machine learning algorithms to classify images of the retina of patients without dilating their pupils.

Hypersound Medical is focused on developing non-invasive neuromodulatory devices that utilize neurostimulation techniques to address chronic pain conditions. The company's products employ microwave energy to stimulate nerve cells, offering pain relief for various ailments, including arthritis, back pain, and neuropathic pain. By enhancing pain management, Hypersound Medical aims to improve patient function and reduce reliance on pain medication. Their approach encompasses various stimulation methods, such as peripheral nerve stimulation and spinal cord stimulation, positioning the company as a key player in the field of pain relief technology.

Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

UCHU Biosensors develops a platform of tooth mounted sensors to effortlessly track health through saliva.

Levisonics is a manufacturer of advanced blood coagulation instruments that specialize in non-contact analysis for blood coagulation and fluid quality control testing. Their products facilitate the assessment of bleeding and thrombosis risks through innovative fluid rheological measurement techniques. In addition to medical applications, Levisonics' technology can be employed in real-time monitoring of the quality of food, liquid, and gel products during production or processing, ensuring safety and compliance in various industries.

Visicell Medical is a company focused on developing innovative medical imaging technology that enhances the early detection and diagnosis of diseases. It specializes in creating safe and biodegradable stem cell tracking tools, which facilitate real-time monitoring of stem cells implanted in patients. These tools are designed for use in both clinical and pre-clinical settings, allowing healthcare professionals to track stem cell progress effectively. In addition to stem cell tracking, Visicell Medical offers specialized image capture systems and analysis tools that provide high-resolution, three-dimensional views of tissues and cells. This technology aids in the identification of abnormalities, enabling earlier intervention and improved treatment outcomes for patients, while also aiming to reduce overall healthcare costs.

Cytocybernetics is a biotechnology company that specializes in cellular electrophysiology. The company has developed the Cybercyte, a user-friendly plug-and-play dynamic clamp system designed for ease of use in research settings. In addition to its innovative products, Cytocybernetics offers a comprehensive range of contract research organization (CRO) services, which include FDA-mandated drug safety screening, custom electrophysiology, custom modeling, and custom analysis. These services are aimed at assisting clients in the development and evaluation of various cellular products, ensuring that they meet regulatory requirements and scientific standards.

Amphix Bio is engaged in the development of advanced therapeutic materials aimed at regenerative medicine. The company specializes in creating nanofiber materials that replicate the structure and dynamic characteristics of human tissues. By integrating biological signals, these materials instruct cells to activate regenerative processes. Amphix Bio's innovations enable the development of therapies designed to repair a variety of tissues, including bone, cartilage, muscle, cardiovascular tissues, and the brain and spinal cord. The promising results observed in both preclinical and clinical trials highlight the potential of Amphix Bio's approach in transforming therapeutic applications in medicine.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

GeniPhys LLC, founded in 2014 and based in Zionsville, Indiana, focuses on the commercialization of standardized tunable collagen polymers, known as collymers, and collagen-fibril materials for research and medical applications. The company manufactures research-grade collymers and polymerization reagents, allowing users to customize 3D collagen-fibril matrices for various uses, including in-vitro tissue systems for drug discovery, toxicity testing, and fundamental cell research. GeniPhys's products cater to the advanced design of engineered tissue and organ constructs, as well as 3D bioprinting applications. Their offerings include polymerization kits, solutions, buffers, supplements, and various chemical reagents. The company provides its products through an online platform, enabling a wide reach to researchers and medical professionals.

Juggernaut Life Sciences specializes in developing innovative medical technologies. They focus on four key areas: medicine, image guidance, robotics, and artificial intelligence. Their primary business is designing and developing medical devices and platforms that can perform routine procedures with minimal human intervention, aiming to enhance safety and reduce costs for their clients.

Taurus Diagnostics is a health-tech company focused on enhancing the diagnostic process for men suspected of having prostate cancer. The company employs data-centric artificial intelligence solutions to improve the accuracy of magnetic resonance imaging (MRI), which helps prevent unnecessary biopsies. Its AI algorithm has been trained on a vast dataset of patient examples to reliably detect lesions indicative of prostate cancer. This technology allows physicians to identify patients who require biopsies more effectively and provides precise locations of the detected lesions, thereby supporting better clinical decision-making.

Intelligent Medicine specializes in software and simulation services focused on enhancing safety in medical environments through innovative technologies. The company has developed a simulation platform that enables architects and facility stakeholders to evaluate and optimize building designs and operational protocols. By testing various designs and protocols, the platform helps to identify areas for improvement, thereby reducing the likelihood of infectious disease transmission and alleviating user congestion. This capability allows for a rapid feedback loop, supporting the planning and implementation of effective safety policies and design strategies to improve overall outcomes in healthcare settings.

InvVax, Inc. is a vaccine development company based in Los Angeles, California, founded in 2012. The company focuses on creating innovative vaccines, with its primary product being a universal influenza vaccine aimed at preventing pandemics. Utilizing a proprietary platform, InvVax's technology analyzes influenza proteins to address virus mutations, thereby enhancing the effectiveness of vaccines. In addition to its work on influenza, InvVax is exploring vaccine candidates for other viral infections, including HIV, Hepatitis B, and Hepatitis C.

Nostopharma specializes in developing treatments for pathologic bone growth, aiming to prevent rare bone diseases and minimize complications from traumatic injuries. The company offers a nanoparticle drug delivery system that addresses soft tissue trauma complications, facilitating the formation of new bone after surgeries, burns, and other traumatic incidents. By enhancing the recovery process, Nostopharma's innovative approach supports healthcare providers in improving clinical outcomes for patients undergoing surgical procedures related to post-traumatic injuries. Additionally, the company's efforts contribute to reducing rehabilitation costs for society.

SafeBVM is a medical device company focused on enhancing patient safety during manual ventilation. Its flagship product, Sotair, is designed to mitigate the risks associated with excessive ventilation, which can lead to complications such as stomach insufflation and acute respiratory distress syndrome. The device employs a flow-blocking and pressure-control valve mechanism that regulates airflow and ensures optimal ventilation parameters based on individual patient needs, including airway resistance and lung compliance. By addressing the issue of inadvertent hyperventilation, SafeBVM aims to improve the safety and effectiveness of manual resuscitation techniques used by healthcare providers.

Aurie is a medical device company based in New York, established in 2018. It focuses on developing a reusable urinary catheterization system aimed at improving the quality of life for individuals with disabilities. By providing a convenient, discreet, and hygienic catheterization option, Aurie seeks to reduce the risk of infections and enhance users' confidence and control over their healthcare needs. The company's innovative approach empowers users to manage their condition more effectively, enabling them to lead active and fulfilling lives.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

Alienbyte specializes in providing medical images and corresponding labels essential for the advanced analysis of human and animal anatomy, as well as for training artificial intelligence algorithms. The company has developed a web application that features a user-friendly interface and tools for annotating three-dimensional tomographic images. By incorporating artificial intelligence and algorithmic techniques, Alienbyte enhances the efficiency of the labeling process, thereby increasing the utility of medical images for researchers, healthcare professionals, and patients. This focus on innovative labeling solutions positions Alienbyte as a valuable resource in the medical imaging field.

Reselute is a medical technology company focused on addressing orthopedic implant-related infections. The company specializes in designing, developing, and validating innovative orthopedic spacers that serve as a treatment solution. By leveraging advanced technologies, Reselute aims to enhance the efficiency of medical treatments and improve patient care, ultimately assisting healthcare providers in delivering timely and effective interventions for their patients.

Oncurie specializes in developing targeted radionuclide therapies aimed at treating metastatic cancer. The company employs innovative molecular radionuclide technology to deliver radionuclides selectively to metastatic tissues, enhancing treatment efficacy. By focusing on this advanced therapeutic approach, Oncurie seeks to provide healthcare providers with the tools needed to effectively cure patients suffering from breast cancer and other metastatic conditions.

Optical Waters specializes in providing innovative disinfection solutions aimed at ensuring the delivery of clean and safe products for end users. The company has developed patent-pending optical fibers that emit germicidal ultraviolet light along their entire length, functioning similarly to a glowstick. These optical fibers are designed to be stable in water and can be integrated into complex geometries and narrow-diameter channels, such as piping or tubing. This technology allows for effective disinfection in challenging environments, making it suitable for various applications where cleanliness and safety are paramount.

Bired Imaging specializes in infrared imaging technology aimed at enhancing breast cancer detection and localization, particularly in patients with dense breast tissue. Their medical imaging platform employs thermography and a proprietary computerized detection algorithm, which allows for the accurate identification of tumor size and location. This innovative approach enables healthcare professionals to detect high-risk patients at earlier stages, improving screening efficacy while also being cost-effective. Bired Imaging's solutions serve as an important adjunctive technology in breast cancer screening, contributing to more precise diagnostic processes.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

PZA Innovation is a biotechnology company focused on developing a reliable testing method for pyrazinamide, a first-line drug used in tuberculosis treatment. The company employs reverse engineering techniques to determine the specific conditions under which pyrazinamide is effective in vitro, thereby enhancing its action against mycobacterium tuberculosis in a living host. By improving the understanding of pyrazinamide susceptibility, PZA Innovation aims to enable healthcare professionals to offer a next-generation treatment that could potentially shorten the duration of tuberculosis therapy for patients.

IntuiTap Medical, established in 2016 and based in Houston, Texas, specializes in manufacturing innovative medical devices. Its flagship product is a handheld device designed to enhance the precision and efficiency of spinal punctures, such as lumbar punctures, spinal anesthesia, and epidurals. This device, the first of its kind, integrates imaging technology with needle guidance and analytics, aiming to eliminate the guesswork, frustration, and pain traditionally associated with these procedures. By improving accuracy and efficiency, IntuiTap's solution aims to reduce procedural costs and instill confidence in both clinicians and patients.

MBF Therapeutics, Inc. is a veterinary oncology company that specializes in developing and commercializing innovative therapies for cancer treatment in dogs and cats. The company's product portfolio features targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing healthy tissues. Key products include MBFT-101, a combination therapy for sarcomas and lymphoma that utilizes a proprietary polyamine transport inhibitor alongside a potent inhibitor of ornithine decarboxylase, and MBFT-102, an immunotherapy based on the tumor suppressor/cytokine mda-7/IL24, which has shown promise in human clinical trials for various advanced cancers. Additionally, MBF Therapeutics is advancing a gene-based vaccine platform aimed at improving treatments for both cancer and infectious diseases in animals, with the potential to transform veterinary medicine. The company is located in Ambler, Pennsylvania, and maintains a strategic partnership with the Lankenau Institute for Medical Research.

Huxley Medical is a private company focused on the development of medical devices. The company operates a flexible medical platform that aims to ensure continuity of care for patients, regardless of their location or healthcare system. By collaborating with leading clinicians and basic science researchers, Huxley Medical creates and markets innovative devices and algorithms. This approach enhances user access to a wide range of disease diagnoses and treatment options, ultimately improving patient care and outcomes.

Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.

Vulcan Biologics is a biotechnology company based in Irvine, California, established in 2019. It specializes in the modulation of the microbiome through the use of bacteriophages, which are viruses that specifically infect bacteria without harming human cells. This innovative platform aims to achieve stable and persistent changes in the gut microbiome, facilitating the treatment of gluten-related disorders such as gluten sensitivity and celiac disease. By altering the composition of gut bacteria, Vulcan Biologics enables healthcare providers to offer targeted therapeutic solutions for individuals affected by these conditions.

Astek Diagnostics is focused on developing a precision diagnostic platform that assists physicians in prescribing appropriate antibiotics for patients suffering from bacterial sepsis within one hour. The company’s technology utilizes a single-use cartridge to rapidly detect bacterial infections in urine by measuring the oxygen consumption of various bacterial species. This innovative approach not only speeds up the identification process but also aids in combating antibiotic resistance through effective susceptibility testing.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Akttyva Therapeutics specializes in the development of targeted therapeutics aimed at addressing cell barrier dysfunction associated with various vascular disorders. The company leverages a deep understanding of biological pathways, along with advanced artificial intelligence and machine learning techniques, to design solutions that enhance the treatment of these conditions. Through its innovative approach, Akttyva Therapeutics seeks to provide healthcare professionals with effective tools to manage and treat disorders related to cell barriers.

CorInnova Incorporated, founded in 2004 and based in Houston, Texas, specializes in device-based therapies aimed at treating congestive heart failure. The company is known for its innovative non-blood-contacting soft robotic cardiac assist device, which has the potential to significantly increase the number of heart failure patients eligible for life-saving device therapies. By focusing on advanced technological solutions, CorInnova seeks to improve outcomes for individuals suffering from this serious condition.

Synvivia, Inc. is a biotechnology company founded in 2016 and based in Berkeley, California. It specializes in developing synthetic biology products, particularly ON-OFF switches for genetically engineered organisms. These protein switches can be controlled by small molecules, allowing for precise manipulation of biological functions. By integrating these switches into organisms, Synvivia aims to create engineered life forms that can be effectively used in healthcare. The company also focuses on generating biosensors that enhance enzymatic activities, facilitating easier disease diagnosis and enabling healthcare providers to deliver appropriate treatments.

OPOS operates a patient monitoring and opioid prescriber compliance platform designed to assist primary care and pain specialists across various practice settings. The company focuses on ensuring that opioid prescribers adhere to guidelines set by the Centers for Disease Control and Prevention, state authorities, and medical boards. By providing documented evidence of compliance, along with clinical decision support, OPOS enables healthcare providers to enhance patient outcomes and assess individual and collective risks associated with patients, prescribers, and practices. Their services not only promote regulatory compliance but also aim to reduce prescribing risks and administrative overhead, thus generating revenue through improved operational efficiency in opioid treatment.

Cision Vision is a developer and supplier of advanced imaging medical products focused on enhancing the examination of lymph nodes. Their innovative technology allows pathologists to visualize, scan, and record lymph nodes in real time with high contrast, without the need for injections or radiation. This capability supports the modernization of pathology practices, ensuring consistency and high-quality care in medical diagnostics. By providing these biotechnology tools, Cision Vision aims to improve the efficiency and accuracy of lymph node assessments in clinical settings.

Nasus Medical is focused on addressing the challenge of inadequate early treatment for chronic sinusitis through the development of a non-invasive drug-delivery device. This innovative solution allows patients to manage their condition in a non-clinical setting, minimizing the need for systemic medications, injections, or invasive procedures that often come with significant side effects or high costs. The device is designed to be rapidly effective and easily self-administered, offering a more accessible and affordable alternative for individuals suffering from chronic rhinosinusitis.

Pragma Health provides digital healthcare services. They permit users to perform different tests for cardiovascular, hematology, infectious diseases, and others in the privacy of their home and provide accurate, immediate results, enabling them to get a convenient, cost-effective, and accurate healthcare testing process.

Aracari Biosciences specializes in developing advanced 3D Vascularized Micro-Organ platforms aimed at improving the drug discovery process. These platforms enhance the biological authenticity of pre-clinical testing by allowing for real-time imaging of vessel morphology, which facilitates the investigation of lead compound efficacy against tumors in a three-dimensional environment. The technology is designed to adapt to various physiological conditions and can be perfused with fluorophore-tagged dextrans of different molecular weights. This capability assists pharmaceutical companies in making informed decisions and accelerates the development of new drugs.

Koda Health, Inc. is a Houston-based company that develops a data-driven, video-based interactive platform aimed at enhancing communication between healthcare providers and elderly patients. Incorporated in 2020, Koda Health offers a digital care-planning solution that guides patients through personalized end-of-life discussions, empowering them to make informed decisions about their medical care. The platform utilizes artificial intelligence to facilitate conversations regarding patients' quality of life preferences, power of attorney, and emergency contacts, ensuring that healthcare providers have necessary information available when patients are unable to make decisions. By prioritizing patients' healthcare preferences, Koda Health not only helps reduce inappropriate care but also generates revenue for health systems, minimizing unnecessary expenditures while creating valuable data on patient care preferences.

Green Sun Medical, LLC is a medical device company based in Fort Collins, Colorado, specializing in the design, development, and manufacturing of orthotic braces for treating Adolescent Idiopathic Scoliosis (AIS) and Kyphosis. Founded in 2013, the company focuses on creating a dynamic spinal alignment brace that applies continuous corrective pressure to the spine, assisting in the management of spinal deformities. This innovative brace not only promotes effective treatment but also enables physicians to monitor its performance remotely in real-time, thereby enhancing patient care and recovery outcomes. Green Sun Medical is dedicated to advancing spinal health through its technology-driven solutions.

Felix Biotechnology, founded in 2019 and based in San Francisco, California, is focused on developing biotherapeutics aimed at addressing microbial challenges in human health, particularly antibiotic-resistant strains of bacteria and fungi. The company aims to accelerate the deployment of innovative treatments for infectious diseases, enabling healthcare professionals to manage these urgent health threats effectively. Through its targeted approach, Felix Biotechnology seeks to provide precise and effective solutions to combat the growing issue of antibiotic resistance.

Biochip Labs, founded in 2019 and headquartered in Cleveland, Ohio, specializes in laboratory testing services for blood disorders, particularly sickle cell disease and thalassemia. The company offers a variety of proprietary microfluidic biomarker assays that assess blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the efficacy of emerging targeted and curative therapies, allowing clinicians to effectively monitor patient responses to treatment. By focusing on accurate and high-quality testing, Biochip Labs aims to advance the understanding and management of blood disorders.

CollaMedix specializes in the development of collagen-based medical devices aimed at addressing soft tissue repair and augmentation. The company focuses on treating stress urinary incontinence in women, a condition that results in urine leakage during activities such as laughing, coughing, sneezing, lifting, and exercising. CollaMedix utilizes proprietary collagen materials to create a bio-inductive scaffold, which is a strong fabric designed to support human tissue and facilitate rapid cell integration. This innovative approach allows researchers to explore new and effective treatments for female pelvic health, ensuring safety and efficacy in their medical solutions.

Frontier Bio Corporation, based in Oakland, California, develops and manufactures advanced bioprinting technologies to create lab-grown human tissues. Established in 2018, the company offers the FLUX-1, a 3D bioprinter that integrates conventional bioprinting methods with electro-hydrodynamic printing capabilities. This technology enables the production of complex tissues, such as skin, cartilage, and bone, while also facilitating drug toxicity testing, tissue implants, drug screening, and disease modeling. Frontier Bio aims to replace animal studies with ethically developed human tissues, ultimately working towards eliminating the organ transplant waitlist and improving patient outcomes. The company focuses on achieving complete cell survivability during the printing process, ensuring the viability of the printed tissues for various medical applications.